Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21880013 | 0.92 | RORC (0.35) | RORC | |
| SCHEMBL23930988 | 0.86 | MAP2K4 (0.31) | MAP2K4 | |
| SCHEMBL23930987 | 0.85 | MAP2K4 (0.31) | MAP2K4 | |
| SCHEMBL26977231 | 0.79 | MAP2K4 (0.34) | MAP2K4 | |
| SCHEMBL23930840 | 0.78 | MAP2K4 (0.35) | MAP2K4 | |
| SCHEMBL13210054 | 0.74 | MAP2K4 (0.36) | MAP2K4 | |
| SCHEMBL30833750 | 0.73 | MAP2K4 (0.39) | RORCMAP2K4 | |
| SCHEMBL21879928 | 0.71 | RHEB (0.31) | — | |
| SCHEMBL10143378 | 0.71 | MAP2K4 (0.34) | MAP2K4 | |
| SCHEMBL1316854 | 0.71 | PDGFRA (0.42) | RORCMAP2K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12065430-B2 | Indazole compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2024-08-20 | — | — | US | disclosed |
| EP-3871673-B1 | NOVEL INDAZOLE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO LTD (JP) | 2024-01-03 | — | — | EP | disclosed |
| US-20230181536-A1 | ANTICANCER COMBINATION THERAPY WITH N-(1-ACRYLOYL-AZETIDIN-3-YL)-2-((1H-INDAZOL-3-YL)AMINO)METHYL)-1H-IMIDAZOLE-5-CARBOXAMIDE INHIBITOR OF KRAS-G12C | TAIHO PHARMACEUTICAL CO LTD (JP) | 2023-06-15 | — | — | US | disclosed |
| US-20210395234-A1 | NOVEL INDAZOLE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO. LTD. (JP) | 2021-12-23 | — | — | US | disclosed |
| WO-2021215545-A1 | ANTICANCER COMBINATION THERAPY WITH N-(1-ACRYLOYL-AZETIDIN-3-YL)-2-((1H-INDAZOL-3-YL)AMINO)METHYL)-1H-IMIDAZOLE-5-CARBOXAMIDE INHIBITOR OF KRAS-G12C | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2021-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12065430-B2 | Indazole compound or salt thereof | RCOR3, H1-3, BICRA | RORC 529/4885MAP2K4 2356/4885 |
| US-20230181536-A1 | ANTICANCER COMBINATION THERAPY WITH N-(1-ACRYLOYL-AZETIDIN-3-YL)-2-((1H-INDAZOL-3-YL)AMINO)METHYL)-1H-IMIDAZOLE-5-CARBOXAMIDE INHIBITOR OF KRAS-G12C | KRAS, NRAS, HRAS | RORC 1887/4885MAP2K4 679/4885 |
| US-20210395234-A1 | NOVEL INDAZOLE COMPOUND OR SALT THEREOF | HDAC11, RCOR3, BICRA | RORC 753/4885MAP2K4 1655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.